Table 1.

Selected FDA approved agents with potential for repurposing for disease modifying action in DLB

Agent	Mechanism of action	Clinical trials for DLB
Ambroxol	Mucolytic agent; inhibits the NO-dependent activation of soluble guanylate cyclase	None
Metformin	Indirectly activates AMPK through inhibition of the mitochondrial respiration chain complex 1	None
Nilotinib	Tyrosine kinase inhibitor	ClinicalTrials.gov Identifier: NCT04002674
Bosutinib	Tyrosine kinase inhibitor	ClinicalTrials.gov Identifier: NCT03888222
Rasagiline	Monoamine oxidase inhibitor	None
Salbutamol	Beta2-agonist	None
Liraglutide	Glucagon-like peptide-1 (GLP-1) receptor agonist	None
Exenatide	Glucacon-like peptide-1(GLP-1) receptor agonist	None
Candesartan	Angiotensin II receptor antagonist	None
Telmisartan	Angiotensin II receptor antagonist	None
Etanercept	Biologic tumor necrosis factor (TNF) inhibitor	None
Fasudil	Rho-kinase inhibitor	None
Lenalidomide	Cyclooxygenase-2 (COX-2) inhibitor	None